| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 137 | 2022 | 195 | 18.450 |
Why?
|
| Platelet Aggregation Inhibitors | 148 | 2022 | 373 | 15.410 |
Why?
|
| Myocardial Infarction | 172 | 2022 | 807 | 12.020 |
Why?
|
| Percutaneous Coronary Intervention | 73 | 2022 | 137 | 10.990 |
Why?
|
| Hemorrhage | 92 | 2022 | 328 | 6.570 |
Why?
|
| Ticlopidine | 65 | 2017 | 118 | 6.550 |
Why?
|
| Fibrinolytic Agents | 43 | 2022 | 377 | 5.730 |
Why?
|
| Coronary Artery Disease | 48 | 2022 | 696 | 5.500 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 60 | 2018 | 80 | 5.290 |
Why?
|
| Coronary Artery Bypass | 56 | 2020 | 218 | 5.260 |
Why?
|
| Coronary Disease | 51 | 2020 | 358 | 5.230 |
Why?
|
| Anticoagulants | 49 | 2022 | 356 | 5.090 |
Why?
|
| Adenosine Monophosphate | 34 | 2022 | 41 | 5.020 |
Why?
|
| Pyridines | 38 | 2019 | 261 | 4.980 |
Why?
|
| Randomized Controlled Trials as Topic | 73 | 2022 | 931 | 4.390 |
Why?
|
| Cardiovascular Diseases | 51 | 2022 | 940 | 4.360 |
Why?
|
| Angioplasty, Balloon, Coronary | 62 | 2017 | 178 | 4.220 |
Why?
|
| Electrocardiography | 67 | 2022 | 601 | 3.950 |
Why?
|
| Adenosine | 30 | 2016 | 165 | 3.280 |
Why?
|
| Cardiology | 24 | 2021 | 140 | 3.060 |
Why?
|
| Humans | 476 | 2022 | 68618 | 3.050 |
Why?
|
| Myocardial Ischemia | 32 | 2020 | 172 | 3.020 |
Why?
|
| Double-Blind Method | 114 | 2020 | 1738 | 2.980 |
Why?
|
| Aged | 274 | 2022 | 14862 | 2.850 |
Why?
|
| Lactones | 19 | 2018 | 64 | 2.850 |
Why?
|
| Myocardial Revascularization | 27 | 2020 | 56 | 2.840 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 34 | 2022 | 35 | 2.790 |
Why?
|
| Aspirin | 41 | 2022 | 295 | 2.700 |
Why?
|
| Treatment Outcome | 173 | 2022 | 7029 | 2.680 |
Why?
|
| Enoxaparin | 26 | 2022 | 51 | 2.460 |
Why?
|
| Venous Thromboembolism | 15 | 2022 | 117 | 2.410 |
Why?
|
| Angina, Unstable | 29 | 2020 | 50 | 2.300 |
Why?
|
| Middle Aged | 269 | 2021 | 21147 | 2.300 |
Why?
|
| Benzamides | 15 | 2019 | 156 | 2.290 |
Why?
|
| Stroke | 49 | 2022 | 2163 | 2.200 |
Why?
|
| Female | 305 | 2022 | 38074 | 2.180 |
Why?
|
| Peptides | 30 | 2017 | 455 | 2.180 |
Why?
|
| Male | 303 | 2022 | 37321 | 2.150 |
Why?
|
| Biomedical Research | 12 | 2019 | 310 | 2.110 |
Why?
|
| Thrombolytic Therapy | 18 | 2022 | 233 | 1.990 |
Why?
|
| Risk Factors | 102 | 2022 | 5731 | 1.880 |
Why?
|
| Factor Xa Inhibitors | 19 | 2019 | 43 | 1.880 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 143 | 1.870 |
Why?
|
| Antibodies, Monoclonal, Humanized | 16 | 2022 | 151 | 1.810 |
Why?
|
| American Heart Association | 18 | 2021 | 142 | 1.800 |
Why?
|
| Coronary Angiography | 58 | 2022 | 866 | 1.800 |
Why?
|
| Risk Assessment | 61 | 2022 | 2007 | 1.660 |
Why?
|
| Thrombosis | 17 | 2021 | 218 | 1.560 |
Why?
|
| Cardiovascular System | 4 | 2021 | 85 | 1.560 |
Why?
|
| Conflict of Interest | 4 | 2017 | 48 | 1.550 |
Why?
|
| Stents | 30 | 2022 | 657 | 1.550 |
Why?
|
| Evidence-Based Medicine | 19 | 2020 | 438 | 1.540 |
Why?
|
| Heparin | 23 | 2017 | 205 | 1.470 |
Why?
|
| Coronary Thrombosis | 15 | 2019 | 45 | 1.470 |
Why?
|
| Acute Disease | 37 | 2021 | 658 | 1.450 |
Why?
|
| Follow-Up Studies | 69 | 2020 | 3259 | 1.440 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 154 | 1.430 |
Why?
|
| Time Factors | 67 | 2021 | 4655 | 1.420 |
Why?
|
| Antibodies, Monoclonal | 15 | 2018 | 511 | 1.420 |
Why?
|
| Postoperative Complications | 20 | 2019 | 1615 | 1.420 |
Why?
|
| Drug Therapy, Combination | 41 | 2021 | 649 | 1.300 |
Why?
|
| Kaplan-Meier Estimate | 36 | 2020 | 536 | 1.270 |
Why?
|
| Receptors, Thrombin | 10 | 2018 | 18 | 1.220 |
Why?
|
| Research Report | 6 | 2021 | 35 | 1.220 |
Why?
|
| United States | 70 | 2021 | 7367 | 1.220 |
Why?
|
| Drug-Eluting Stents | 6 | 2016 | 51 | 1.210 |
Why?
|
| Proportional Hazards Models | 40 | 2019 | 792 | 1.210 |
Why?
|
| Pandemics | 8 | 2021 | 352 | 1.190 |
Why?
|
| Dose-Response Relationship, Drug | 32 | 2018 | 1745 | 1.160 |
Why?
|
| Clinical Trials as Topic | 20 | 2019 | 848 | 1.160 |
Why?
|
| Anticholesteremic Agents | 8 | 2022 | 49 | 1.150 |
Why?
|
| Atherosclerosis | 4 | 2022 | 204 | 1.130 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 113 | 1.070 |
Why?
|
| ST Elevation Myocardial Infarction | 6 | 2022 | 10 | 1.050 |
Why?
|
| Academic Medical Centers | 6 | 2022 | 281 | 1.050 |
Why?
|
| Betacoronavirus | 5 | 2020 | 116 | 1.040 |
Why?
|
| Hospitalization | 21 | 2022 | 978 | 1.040 |
Why?
|
| Incidence | 43 | 2022 | 1603 | 1.040 |
Why?
|
| Research Design | 12 | 2019 | 729 | 1.030 |
Why?
|
| Cardiac Catheterization | 16 | 2020 | 419 | 1.020 |
Why?
|
| Peptide Fragments | 10 | 2017 | 483 | 0.970 |
Why?
|
| Pulmonary Embolism | 6 | 2018 | 253 | 0.920 |
Why?
|
| Tyrosine | 12 | 2016 | 196 | 0.900 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 18 | 0.890 |
Why?
|
| Creatine Kinase, MB Form | 12 | 2018 | 20 | 0.880 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2022 | 212 | 0.860 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2019 | 84 | 0.840 |
Why?
|
| Pyridones | 7 | 2019 | 40 | 0.830 |
Why?
|
| Atrial Fibrillation | 6 | 2022 | 249 | 0.830 |
Why?
|
| Venous Thrombosis | 8 | 2022 | 125 | 0.820 |
Why?
|
| Patient Selection | 9 | 2019 | 592 | 0.810 |
Why?
|
| Wildfires | 1 | 2021 | 5 | 0.770 |
Why?
|
| United States Food and Drug Administration | 5 | 2014 | 131 | 0.770 |
Why?
|
| Students, Medical | 2 | 2022 | 210 | 0.770 |
Why?
|
| Propionates | 4 | 2006 | 21 | 0.770 |
Why?
|
| Climate Change | 1 | 2021 | 17 | 0.770 |
Why?
|
| Pyrazoles | 7 | 2019 | 190 | 0.760 |
Why?
|
| Registries | 12 | 2019 | 733 | 0.760 |
Why?
|
| Prognosis | 30 | 2022 | 2093 | 0.760 |
Why?
|
| Naphthalenes | 4 | 2006 | 47 | 0.760 |
Why?
|
| Global Health | 9 | 2021 | 136 | 0.750 |
Why?
|
| Infusions, Intravenous | 19 | 2018 | 334 | 0.750 |
Why?
|
| Saphenous Vein | 11 | 2016 | 61 | 0.750 |
Why?
|
| Syndrome | 28 | 2007 | 255 | 0.740 |
Why?
|
| Secondary Prevention | 12 | 2021 | 291 | 0.730 |
Why?
|
| Air Pollution | 4 | 2021 | 54 | 0.730 |
Why?
|
| Cholesterol, LDL | 12 | 2022 | 161 | 0.730 |
Why?
|
| Survival Rate | 28 | 2020 | 1056 | 0.700 |
Why?
|
| Diabetes Complications | 5 | 2019 | 249 | 0.700 |
Why?
|
| Immunoglobulin Fab Fragments | 11 | 2016 | 48 | 0.690 |
Why?
|
| Graft Occlusion, Vascular | 14 | 2016 | 73 | 0.680 |
Why?
|
| Rural Health | 1 | 2020 | 66 | 0.680 |
Why?
|
| Endpoint Determination | 5 | 2018 | 82 | 0.680 |
Why?
|
| Hospital Mortality | 19 | 2019 | 384 | 0.680 |
Why?
|
| Societies, Medical | 7 | 2021 | 403 | 0.670 |
Why?
|
| Forecasting | 7 | 2020 | 277 | 0.670 |
Why?
|
| Research Personnel | 3 | 2022 | 83 | 0.670 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 4 | 2022 | 4 | 0.660 |
Why?
|
| Survival Analysis | 25 | 2018 | 714 | 0.650 |
Why?
|
| Health Policy | 2 | 2019 | 221 | 0.650 |
Why?
|
| Rural Health Services | 1 | 2020 | 101 | 0.640 |
Why?
|
| Clinical Medicine | 1 | 2018 | 20 | 0.640 |
Why?
|
| Heart Diseases | 9 | 2018 | 276 | 0.640 |
Why?
|
| Purinergic P2 Receptor Antagonists | 8 | 2011 | 10 | 0.630 |
Why?
|
| Aged, 80 and over | 41 | 2020 | 4848 | 0.630 |
Why?
|
| Biomarkers | 23 | 2022 | 1593 | 0.630 |
Why?
|
| Radial Artery | 7 | 2019 | 43 | 0.630 |
Why?
|
| Cross Infection | 1 | 2020 | 195 | 0.620 |
Why?
|
| Creatinine | 10 | 2016 | 243 | 0.610 |
Why?
|
| Career Choice | 3 | 2019 | 98 | 0.590 |
Why?
|
| Sirolimus | 3 | 2015 | 118 | 0.590 |
Why?
|
| Perioperative Care | 5 | 2018 | 100 | 0.590 |
Why?
|
| Industry | 2 | 2010 | 28 | 0.590 |
Why?
|
| Angioplasty | 3 | 2011 | 118 | 0.580 |
Why?
|
| Drug Administration Schedule | 15 | 2019 | 567 | 0.580 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2022 | 1085 | 0.580 |
Why?
|
| Artificial Intelligence | 1 | 2018 | 159 | 0.570 |
Why?
|
| Blood Transfusion | 9 | 2018 | 205 | 0.560 |
Why?
|
| Hirudins | 5 | 2015 | 32 | 0.560 |
Why?
|
| Rural Population | 1 | 2020 | 398 | 0.550 |
Why?
|
| Pyridoxal Phosphate | 5 | 2008 | 9 | 0.550 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 225 | 0.550 |
Why?
|
| Hypercholesterolemia | 6 | 2020 | 86 | 0.540 |
Why?
|
| Education, Medical | 2 | 2021 | 147 | 0.530 |
Why?
|
| Health Services Misuse | 1 | 2016 | 15 | 0.530 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2022 | 101 | 0.530 |
Why?
|
| Coronary Stenosis | 8 | 2019 | 246 | 0.520 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2015 | 202 | 0.510 |
Why?
|
| Education, Medical, Continuing | 2 | 2021 | 136 | 0.500 |
Why?
|
| Delivery of Health Care | 8 | 2021 | 445 | 0.490 |
Why?
|
| Oligonucleotides | 8 | 2014 | 34 | 0.490 |
Why?
|
| Drug Overdose | 1 | 2015 | 67 | 0.490 |
Why?
|
| Glomerular Filtration Rate | 6 | 2016 | 274 | 0.480 |
Why?
|
| Heart Failure | 11 | 2017 | 1180 | 0.480 |
Why?
|
| Publication Bias | 2 | 2013 | 8 | 0.480 |
Why?
|
| Primary Prevention | 3 | 2019 | 115 | 0.470 |
Why?
|
| Length of Stay | 6 | 2018 | 780 | 0.470 |
Why?
|
| Administration, Oral | 15 | 2017 | 411 | 0.470 |
Why?
|
| Angina Pectoris | 6 | 2022 | 61 | 0.470 |
Why?
|
| Erythropoietin | 2 | 2013 | 96 | 0.460 |
Why?
|
| Odds Ratio | 19 | 2017 | 880 | 0.460 |
Why?
|
| Femoral Artery | 5 | 2019 | 139 | 0.460 |
Why?
|
| Heparin, Low-Molecular-Weight | 8 | 2008 | 41 | 0.450 |
Why?
|
| Congresses as Topic | 6 | 2021 | 85 | 0.440 |
Why?
|
| Peer Review, Research | 4 | 2014 | 21 | 0.440 |
Why?
|
| Antigens, CD34 | 4 | 2016 | 75 | 0.440 |
Why?
|
| Cause of Death | 11 | 2019 | 241 | 0.440 |
Why?
|
| Coronary Restenosis | 6 | 2015 | 42 | 0.440 |
Why?
|
| Risk | 11 | 2020 | 563 | 0.440 |
Why?
|
| Multicenter Studies as Topic | 13 | 2018 | 186 | 0.440 |
Why?
|
| Troponin | 8 | 2018 | 25 | 0.430 |
Why?
|
| Recurrence | 12 | 2019 | 948 | 0.430 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2008 | 84 | 0.430 |
Why?
|
| Chi-Square Distribution | 12 | 2017 | 546 | 0.420 |
Why?
|
| Prospective Studies | 26 | 2019 | 3705 | 0.420 |
Why?
|
| Academies and Institutes | 3 | 2021 | 31 | 0.420 |
Why?
|
| Internationality | 5 | 2017 | 74 | 0.410 |
Why?
|
| Platelet Aggregation | 5 | 2016 | 127 | 0.410 |
Why?
|
| Telemedicine | 5 | 2018 | 700 | 0.410 |
Why?
|
| Cardiovascular Agents | 9 | 2018 | 82 | 0.410 |
Why?
|
| Publishing | 3 | 2013 | 89 | 0.410 |
Why?
|
| Ventricular Fibrillation | 3 | 2013 | 85 | 0.410 |
Why?
|
| Retrospective Studies | 34 | 2022 | 7277 | 0.410 |
Why?
|
| Angina, Stable | 3 | 2018 | 13 | 0.410 |
Why?
|
| Intracranial Hemorrhages | 5 | 2018 | 80 | 0.400 |
Why?
|
| Metabolic Syndrome | 2 | 2014 | 191 | 0.400 |
Why?
|
| Pyridazines | 3 | 2017 | 7 | 0.400 |
Why?
|
| Hydrazones | 3 | 2017 | 11 | 0.400 |
Why?
|
| Stem Cells | 4 | 2016 | 248 | 0.390 |
Why?
|
| Video Recording | 1 | 2012 | 145 | 0.390 |
Why?
|
| Decision Making | 2 | 2014 | 410 | 0.390 |
Why?
|
| Guideline Adherence | 7 | 2007 | 287 | 0.390 |
Why?
|
| Professionalism | 2 | 2021 | 28 | 0.380 |
Why?
|
| Information Dissemination | 4 | 2016 | 113 | 0.380 |
Why?
|
| Tachycardia, Ventricular | 3 | 2013 | 153 | 0.380 |
Why?
|
| Cardiotonic Agents | 4 | 2017 | 71 | 0.380 |
Why?
|
| Education, Medical, Graduate | 3 | 2019 | 214 | 0.380 |
Why?
|
| Cost of Illness | 1 | 2012 | 206 | 0.370 |
Why?
|
| Adult | 39 | 2020 | 21403 | 0.370 |
Why?
|
| Postoperative Hemorrhage | 5 | 2018 | 69 | 0.370 |
Why?
|
| Capital Financing | 1 | 2010 | 2 | 0.360 |
Why?
|
| Learning | 1 | 2012 | 186 | 0.360 |
Why?
|
| Severity of Illness Index | 13 | 2018 | 1851 | 0.360 |
Why?
|
| Patient Discharge | 3 | 2020 | 294 | 0.360 |
Why?
|
| Recovery of Function | 2 | 2010 | 506 | 0.360 |
Why?
|
| Advisory Committees | 5 | 2021 | 73 | 0.360 |
Why?
|
| Troponin T | 5 | 2022 | 16 | 0.360 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2017 | 277 | 0.350 |
Why?
|
| Physicians, Women | 2 | 2021 | 23 | 0.350 |
Why?
|
| Blood Coagulation | 4 | 2017 | 123 | 0.340 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 481 | 0.330 |
Why?
|
| Sex Factors | 14 | 2019 | 1266 | 0.330 |
Why?
|
| Inpatients | 4 | 2018 | 208 | 0.330 |
Why?
|
| Health Care Reform | 3 | 2020 | 62 | 0.330 |
Why?
|
| Receptors, Purinergic P2Y12 | 8 | 2012 | 9 | 0.330 |
Why?
|
| Injections, Intravenous | 11 | 2017 | 215 | 0.320 |
Why?
|
| Cardiology Service, Hospital | 3 | 2020 | 11 | 0.320 |
Why?
|
| Maltose | 3 | 2013 | 3 | 0.320 |
Why?
|
| Antithrombin III | 2 | 2006 | 23 | 0.320 |
Why?
|
| Biomedical Technology | 2 | 2018 | 14 | 0.320 |
Why?
|
| Europe | 10 | 2021 | 196 | 0.310 |
Why?
|
| Ramipril | 1 | 2008 | 10 | 0.310 |
Why?
|
| Diabetes Mellitus | 9 | 2022 | 694 | 0.310 |
Why?
|
| Dyslipidemias | 2 | 2019 | 98 | 0.310 |
Why?
|
| Thromboplastin | 2 | 2004 | 21 | 0.310 |
Why?
|
| Consensus | 5 | 2021 | 211 | 0.310 |
Why?
|
| Physicians | 2 | 2019 | 324 | 0.310 |
Why?
|
| Age Factors | 15 | 2017 | 1864 | 0.310 |
Why?
|
| Polysaccharides | 2 | 2008 | 176 | 0.310 |
Why?
|
| Ferric Compounds | 3 | 2013 | 45 | 0.310 |
Why?
|
| Research | 1 | 2009 | 214 | 0.300 |
Why?
|
| Hirudin Therapy | 1 | 2007 | 3 | 0.300 |
Why?
|
| Sulfonamides | 4 | 2014 | 141 | 0.300 |
Why?
|
| Drug Approval | 3 | 2014 | 50 | 0.300 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2017 | 450 | 0.300 |
Why?
|
| Combined Modality Therapy | 11 | 2016 | 951 | 0.300 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2013 | 34 | 0.300 |
Why?
|
| Quinazolinones | 3 | 2012 | 7 | 0.300 |
Why?
|
| Cost-Benefit Analysis | 6 | 2022 | 504 | 0.300 |
Why?
|
| Receptor, PAR-1 | 4 | 2018 | 30 | 0.300 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2008 | 98 | 0.300 |
Why?
|
| Ventricular Remodeling | 1 | 2010 | 318 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 10 | 2021 | 772 | 0.300 |
Why?
|
| Troponin I | 3 | 2013 | 34 | 0.290 |
Why?
|
| Predictive Value of Tests | 13 | 2018 | 1465 | 0.290 |
Why?
|
| Catheterization, Peripheral | 2 | 2019 | 38 | 0.290 |
Why?
|
| Shock, Cardiogenic | 4 | 2007 | 23 | 0.290 |
Why?
|
| Coronary Circulation | 7 | 2013 | 136 | 0.280 |
Why?
|
| Logistic Models | 15 | 2017 | 1420 | 0.280 |
Why?
|
| Tooth Loss | 2 | 2017 | 7 | 0.280 |
Why?
|
| Coronary Vessels | 4 | 2015 | 313 | 0.280 |
Why?
|
| Hypolipidemic Agents | 5 | 2015 | 82 | 0.280 |
Why?
|
| Thrombocytopenia | 3 | 2018 | 122 | 0.280 |
Why?
|
| Cholesterol | 5 | 2022 | 331 | 0.270 |
Why?
|
| Growth Differentiation Factor 15 | 4 | 2022 | 18 | 0.270 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2020 | 11 | 0.270 |
Why?
|
| Heart Ventricles | 1 | 2010 | 738 | 0.270 |
Why?
|
| Cardiac Tamponade | 1 | 2006 | 11 | 0.270 |
Why?
|
| Vascular Patency | 10 | 2016 | 122 | 0.270 |
Why?
|
| Recombinant Proteins | 5 | 2015 | 742 | 0.260 |
Why?
|
| Leadership | 3 | 2022 | 136 | 0.260 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 581 | 0.260 |
Why?
|
| Renal Insufficiency | 4 | 2011 | 121 | 0.250 |
Why?
|
| Databases as Topic | 3 | 2010 | 49 | 0.250 |
Why?
|
| Sex Characteristics | 3 | 2017 | 295 | 0.250 |
Why?
|
| Electronic Health Records | 2 | 2022 | 374 | 0.250 |
Why?
|
| Drug Costs | 3 | 2018 | 87 | 0.250 |
Why?
|
| Quality Improvement | 3 | 2020 | 413 | 0.250 |
Why?
|
| Blood Platelets | 4 | 2016 | 284 | 0.250 |
Why?
|
| Camptothecin | 1 | 2004 | 39 | 0.250 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2022 | 9 | 0.240 |
Why?
|
| Factor IXa | 3 | 2010 | 3 | 0.240 |
Why?
|
| Folic Acid | 1 | 2005 | 123 | 0.240 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 3 | 2016 | 12 | 0.240 |
Why?
|
| Hospitals | 2 | 2020 | 265 | 0.240 |
Why?
|
| Treatment Failure | 7 | 2017 | 216 | 0.230 |
Why?
|
| Veins | 3 | 2017 | 68 | 0.230 |
Why?
|
| Endothelial Cells | 3 | 2013 | 384 | 0.230 |
Why?
|
| Canada | 7 | 2020 | 267 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2019 | 504 | 0.230 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 26 | 0.230 |
Why?
|
| Interdisciplinary Communication | 3 | 2019 | 93 | 0.230 |
Why?
|
| Blood Glucose | 4 | 2017 | 631 | 0.230 |
Why?
|
| Acetates | 5 | 2011 | 74 | 0.230 |
Why?
|
| Ischemia | 4 | 2022 | 229 | 0.220 |
Why?
|
| Air Pollutants | 2 | 2021 | 75 | 0.220 |
Why?
|
| Lipoprotein(a) | 2 | 2020 | 9 | 0.220 |
Why?
|
| Transplantation, Autologous | 5 | 2016 | 145 | 0.220 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2020 | 239 | 0.220 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2016 | 186 | 0.220 |
Why?
|
| Cohort Studies | 10 | 2021 | 2358 | 0.220 |
Why?
|
| Databases, Factual | 5 | 2018 | 622 | 0.220 |
Why?
|
| Hospital Costs | 3 | 2018 | 117 | 0.220 |
Why?
|
| Anemia | 3 | 2018 | 104 | 0.220 |
Why?
|
| Retreatment | 5 | 2015 | 59 | 0.220 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 123 | 0.220 |
Why?
|
| Conservative Treatment | 2 | 2022 | 8 | 0.210 |
Why?
|
| Intention to Treat Analysis | 3 | 2017 | 38 | 0.210 |
Why?
|
| Comorbidity | 11 | 2021 | 1426 | 0.210 |
Why?
|
| Quality of Health Care | 7 | 2021 | 322 | 0.210 |
Why?
|
| Periodicals as Topic | 3 | 2019 | 158 | 0.210 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2015 | 189 | 0.210 |
Why?
|
| Stem Cell Transplantation | 2 | 2013 | 58 | 0.210 |
Why?
|
| Heart Conduction System | 5 | 2008 | 119 | 0.210 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 371 | 0.210 |
Why?
|
| Multivariate Analysis | 13 | 2019 | 1046 | 0.210 |
Why?
|
| Cardiopulmonary Bypass | 6 | 2016 | 250 | 0.210 |
Why?
|
| Brain Ischemia | 2 | 2019 | 665 | 0.210 |
Why?
|
| Patient Readmission | 4 | 2018 | 267 | 0.200 |
Why?
|
| Mortality | 3 | 2018 | 163 | 0.200 |
Why?
|
| Algorithms | 4 | 2014 | 1196 | 0.200 |
Why?
|
| Factor Xa | 4 | 2010 | 10 | 0.200 |
Why?
|
| Schools, Medical | 2 | 2022 | 157 | 0.200 |
Why?
|
| Myocardial Reperfusion | 5 | 2022 | 32 | 0.200 |
Why?
|
| Clinical Clerkship | 1 | 2022 | 63 | 0.200 |
Why?
|
| Exercise | 2 | 2018 | 658 | 0.200 |
Why?
|
| Transfection | 4 | 2016 | 782 | 0.200 |
Why?
|
| Clinical Competence | 2 | 2020 | 657 | 0.190 |
Why?
|
| Return to Work | 1 | 2021 | 6 | 0.190 |
Why?
|
| Disease Management | 4 | 2016 | 248 | 0.190 |
Why?
|
| Faculty | 1 | 2022 | 56 | 0.190 |
Why?
|
| North America | 5 | 2021 | 112 | 0.190 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2016 | 35 | 0.190 |
Why?
|
| Disease Transmission, Infectious | 1 | 2021 | 25 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2022 | 110 | 0.190 |
Why?
|
| Benchmarking | 1 | 2021 | 91 | 0.190 |
Why?
|
| Noncommunicable Diseases | 1 | 2020 | 7 | 0.190 |
Why?
|
| Kidney | 4 | 2016 | 945 | 0.180 |
Why?
|
| Stroke Volume | 9 | 2017 | 586 | 0.180 |
Why?
|
| Ethics, Medical | 1 | 2021 | 86 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2012 | 164 | 0.180 |
Why?
|
| Public Health | 4 | 2021 | 201 | 0.180 |
Why?
|
| Tissue Plasminogen Activator | 9 | 2007 | 296 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2020 | 40 | 0.180 |
Why?
|
| Italy | 1 | 2020 | 36 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 1140 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 14 | 0.180 |
Why?
|
| Aortic Valve Stenosis | 2 | 2012 | 177 | 0.180 |
Why?
|
| Azithromycin | 1 | 2020 | 13 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 136 | 0.180 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2020 | 36 | 0.180 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2020 | 61 | 0.180 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 27 | 0.170 |
Why?
|
| Postoperative Care | 2 | 2013 | 163 | 0.170 |
Why?
|
| Access to Information | 2 | 2020 | 21 | 0.170 |
Why?
|
| Kidney Failure, Chronic | 3 | 2008 | 365 | 0.170 |
Why?
|
| Aptamers, Nucleotide | 3 | 2010 | 15 | 0.170 |
Why?
|
| Body Mass Index | 5 | 2022 | 867 | 0.170 |
Why?
|
| Critical Illness | 2 | 2019 | 191 | 0.170 |
Why?
|
| Safety Management | 1 | 2020 | 73 | 0.170 |
Why?
|
| Policy Making | 1 | 2019 | 51 | 0.170 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 48 | 0.170 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2009 | 50 | 0.170 |
Why?
|
| Oximes | 3 | 2016 | 10 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 362 | 0.170 |
Why?
|
| Azetidines | 2 | 2009 | 6 | 0.170 |
Why?
|
| Kidney Diseases | 3 | 2011 | 307 | 0.170 |
Why?
|
| Thrombin | 4 | 2010 | 117 | 0.170 |
Why?
|
| Placebo Effect | 2 | 2016 | 20 | 0.170 |
Why?
|
| Cardiologists | 1 | 2019 | 9 | 0.160 |
Why?
|
| Authorship | 1 | 2019 | 18 | 0.160 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 20 | 0.160 |
Why?
|
| Sex Distribution | 7 | 2019 | 274 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 2 | 2010 | 101 | 0.160 |
Why?
|
| Hypoalbuminemia | 1 | 2018 | 9 | 0.160 |
Why?
|
| Women's Health Services | 1 | 2018 | 10 | 0.160 |
Why?
|
| Regression Analysis | 7 | 2013 | 737 | 0.160 |
Why?
|
| Specialization | 1 | 2019 | 66 | 0.160 |
Why?
|
| Partial Thromboplastin Time | 5 | 2010 | 57 | 0.160 |
Why?
|
| Bibliometrics | 2 | 2019 | 25 | 0.160 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 29 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 378 | 0.160 |
Why?
|
| Hypertension | 7 | 2016 | 1535 | 0.160 |
Why?
|
| Inflammation | 3 | 2022 | 1030 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 21 | 0.160 |
Why?
|
| Point-of-Care Systems | 2 | 2014 | 115 | 0.150 |
Why?
|
| Phospholipase A2 Inhibitors | 2 | 2016 | 2 | 0.150 |
Why?
|
| Benzaldehydes | 2 | 2016 | 8 | 0.150 |
Why?
|
| Antithrombins | 3 | 2008 | 32 | 0.150 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 91 | 0.150 |
Why?
|
| California | 2 | 2019 | 99 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 77 | 0.150 |
Why?
|
| Women's Health | 1 | 2018 | 148 | 0.150 |
Why?
|
| Trust | 2 | 2020 | 75 | 0.150 |
Why?
|
| Equipment and Supplies | 2 | 2010 | 18 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 88 | 0.150 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 79 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 3 | 2009 | 182 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2018 | 220 | 0.150 |
Why?
|
| Physical Fitness | 1 | 2018 | 117 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 2 | 2018 | 36 | 0.150 |
Why?
|
| Obesity | 4 | 2022 | 1076 | 0.140 |
Why?
|
| Age Distribution | 6 | 2019 | 320 | 0.140 |
Why?
|
| Cardiac Output, Low | 1 | 2017 | 52 | 0.140 |
Why?
|
| Social Media | 1 | 2018 | 59 | 0.140 |
Why?
|
| Hematinics | 3 | 2013 | 52 | 0.140 |
Why?
|
| Quality of Life | 4 | 2022 | 1515 | 0.140 |
Why?
|
| Half-Life | 1 | 2016 | 96 | 0.140 |
Why?
|
| Fasting | 1 | 2017 | 75 | 0.140 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2017 | 40 | 0.140 |
Why?
|
| Bilirubin | 1 | 2016 | 51 | 0.140 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2016 | 10 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2013 | 29 | 0.140 |
Why?
|
| Thrombectomy | 1 | 2019 | 238 | 0.140 |
Why?
|
| Glucaric Acid | 2 | 2013 | 2 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2022 | 596 | 0.140 |
Why?
|
| International Normalized Ratio | 3 | 2010 | 23 | 0.140 |
Why?
|
| Nitric Oxide Synthase | 2 | 2007 | 163 | 0.140 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 137 | 0.140 |
Why?
|
| Ribonucleosides | 2 | 2014 | 5 | 0.140 |
Why?
|
| Mammary Arteries | 1 | 2016 | 18 | 0.140 |
Why?
|
| Peripheral Arterial Disease | 2 | 2014 | 83 | 0.140 |
Why?
|
| Editorial Policies | 1 | 2016 | 32 | 0.140 |
Why?
|
| Cross-Over Studies | 2 | 2015 | 260 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2017 | 153 | 0.130 |
Why?
|
| Aminoimidazole Carboxamide | 2 | 2014 | 25 | 0.130 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 4 | 2018 | 50 | 0.130 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2016 | 141 | 0.130 |
Why?
|
| International Cooperation | 2 | 2021 | 88 | 0.130 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 5 | 0.130 |
Why?
|
| Blood Component Removal | 2 | 2012 | 19 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 1 | 2017 | 167 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 442 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 117 | 0.130 |
Why?
|
| Albuminuria | 1 | 2016 | 171 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2004 | 2689 | 0.130 |
Why?
|
| Linear Models | 4 | 2019 | 521 | 0.130 |
Why?
|
| Data Mining | 1 | 2015 | 45 | 0.130 |
Why?
|
| North Carolina | 2 | 2013 | 224 | 0.130 |
Why?
|
| Everolimus | 1 | 2015 | 26 | 0.130 |
Why?
|
| New Zealand | 4 | 2016 | 28 | 0.120 |
Why?
|
| Education | 2 | 2020 | 83 | 0.120 |
Why?
|
| Foundations | 2 | 2013 | 17 | 0.120 |
Why?
|
| Confidence Intervals | 4 | 2013 | 242 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2015 | 124 | 0.120 |
Why?
|
| Proprotein Convertases | 1 | 2014 | 8 | 0.120 |
Why?
|
| Heart Arrest | 1 | 2015 | 113 | 0.120 |
Why?
|
| Mobile Applications | 1 | 2017 | 138 | 0.120 |
Why?
|
| Iron | 2 | 2013 | 197 | 0.120 |
Why?
|
| Proprotein Convertase 9 | 3 | 2020 | 14 | 0.120 |
Why?
|
| Myocardium | 4 | 2016 | 1204 | 0.120 |
Why?
|
| Developed Countries | 1 | 2014 | 8 | 0.120 |
Why?
|
| Organ Preservation Solutions | 1 | 2014 | 45 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 659 | 0.110 |
Why?
|
| Standard of Care | 1 | 2013 | 22 | 0.110 |
Why?
|
| Research Support as Topic | 2 | 2015 | 58 | 0.110 |
Why?
|
| Internet | 1 | 2016 | 390 | 0.110 |
Why?
|
| Dyspnea | 2 | 2011 | 87 | 0.110 |
Why?
|
| Hemoglobins | 4 | 2018 | 120 | 0.110 |
Why?
|
| Social Responsibility | 1 | 2013 | 39 | 0.110 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2013 | 6 | 0.110 |
Why?
|
| Government Programs | 1 | 2013 | 16 | 0.110 |
Why?
|
| Developing Countries | 1 | 2014 | 106 | 0.110 |
Why?
|
| Creatine Kinase | 4 | 2006 | 46 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 185 | 0.110 |
Why?
|
| Health Promotion | 1 | 2017 | 407 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2013 | 129 | 0.110 |
Why?
|
| DNA | 2 | 2005 | 597 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2012 | 349 | 0.110 |
Why?
|
| Bundle-Branch Block | 1 | 2013 | 50 | 0.110 |
Why?
|
| Patient Care | 1 | 2013 | 61 | 0.110 |
Why?
|
| Animals | 5 | 2019 | 20881 | 0.110 |
Why?
|
| Smoking | 5 | 2008 | 1452 | 0.110 |
Why?
|
| Vascular Diseases | 2 | 2019 | 94 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2013 | 48 | 0.100 |
Why?
|
| Survival | 2 | 2013 | 22 | 0.100 |
Why?
|
| Models, Organizational | 2 | 2017 | 97 | 0.100 |
Why?
|
| Acute Kidney Injury | 2 | 2016 | 232 | 0.100 |
Why?
|
| Simvastatin | 2 | 2009 | 34 | 0.100 |
Why?
|
| Prevalence | 6 | 2014 | 1619 | 0.100 |
Why?
|
| Kidney Function Tests | 1 | 2011 | 114 | 0.100 |
Why?
|
| Forced Expiratory Volume | 1 | 2011 | 87 | 0.100 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 56 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2011 | 137 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2017 | 703 | 0.100 |
Why?
|
| Microcirculation | 1 | 2011 | 77 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2011 | 1451 | 0.100 |
Why?
|
| Clinical Protocols | 2 | 2019 | 172 | 0.100 |
Why?
|
| Models, Economic | 2 | 2018 | 69 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 161 | 0.100 |
Why?
|
| Anastomosis, Surgical | 1 | 2011 | 104 | 0.100 |
Why?
|
| Bradycardia | 1 | 2011 | 45 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2012 | 91 | 0.090 |
Why?
|
| Epoetin Alfa | 1 | 2010 | 23 | 0.090 |
Why?
|
| Liver | 1 | 2016 | 1118 | 0.090 |
Why?
|
| Feasibility Studies | 5 | 2017 | 652 | 0.090 |
Why?
|
| Exercise Test | 4 | 2016 | 242 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 1753 | 0.090 |
Why?
|
| Kinetics | 2 | 2002 | 1047 | 0.090 |
Why?
|
| Models, Biological | 2 | 2004 | 981 | 0.090 |
Why?
|
| Graft Rejection | 2 | 2011 | 458 | 0.090 |
Why?
|
| Therapeutics | 1 | 2010 | 7 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 258 | 0.090 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2010 | 83 | 0.090 |
Why?
|
| Health Expenditures | 1 | 2012 | 170 | 0.090 |
Why?
|
| Antidotes | 2 | 2008 | 21 | 0.090 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2011 | 182 | 0.090 |
Why?
|
| Cooperative Behavior | 3 | 2015 | 235 | 0.090 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 10 | 0.080 |
Why?
|
| Brazil | 3 | 2016 | 48 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2022 | 307 | 0.080 |
Why?
|
| von Willebrand Factor | 1 | 2009 | 47 | 0.080 |
Why?
|
| Warfarin | 1 | 2010 | 93 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2012 | 320 | 0.080 |
Why?
|
| Isoenzymes | 3 | 2005 | 308 | 0.080 |
Why?
|
| Leukocyte Count | 2 | 2013 | 94 | 0.080 |
Why?
|
| Heart Rate | 4 | 2020 | 568 | 0.080 |
Why?
|
| Laboratories | 1 | 2009 | 44 | 0.080 |
Why?
|
| Ethics, Research | 1 | 2009 | 12 | 0.080 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2009 | 18 | 0.080 |
Why?
|
| Apolipoproteins B | 2 | 2022 | 29 | 0.080 |
Why?
|
| Biological Products | 1 | 2010 | 78 | 0.080 |
Why?
|
| Drug Interactions | 2 | 2020 | 289 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 245 | 0.080 |
Why?
|
| Reoperation | 4 | 2015 | 467 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 597 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 248 | 0.080 |
Why?
|
| Diffusion of Innovation | 3 | 2015 | 102 | 0.080 |
Why?
|
| Genetic Engineering | 1 | 2008 | 41 | 0.080 |
Why?
|
| Lipids | 1 | 2010 | 298 | 0.080 |
Why?
|
| Hematologic Agents | 1 | 2007 | 11 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2007 | 238 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2223 | 0.080 |
Why?
|
| Punctures | 2 | 2019 | 35 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 138 | 0.070 |
Why?
|
| omega-N-Methylarginine | 1 | 2007 | 14 | 0.070 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2007 | 13 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 498 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2009 | 1342 | 0.070 |
Why?
|
| Bioterrorism | 1 | 2007 | 12 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 83 | 0.070 |
Why?
|
| C-Reactive Protein | 2 | 2018 | 180 | 0.070 |
Why?
|
| Adolescent | 7 | 2017 | 8912 | 0.070 |
Why?
|
| Health Care Sector | 1 | 2007 | 26 | 0.070 |
Why?
|
| Total Quality Management | 1 | 2007 | 45 | 0.070 |
Why?
|
| Young Adult | 6 | 2017 | 5717 | 0.070 |
Why?
|
| Interinstitutional Relations | 1 | 2007 | 49 | 0.070 |
Why?
|
| Arginine | 1 | 2007 | 102 | 0.070 |
Why?
|
| Cardiac Care Facilities | 1 | 2006 | 3 | 0.070 |
Why?
|
| Vasoconstrictor Agents | 1 | 2007 | 107 | 0.070 |
Why?
|
| Drug Dosage Calculations | 2 | 2019 | 9 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2009 | 232 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2006 | 140 | 0.070 |
Why?
|
| Interprofessional Relations | 2 | 2020 | 188 | 0.070 |
Why?
|
| Piperidines | 2 | 2003 | 123 | 0.070 |
Why?
|
| Patient Safety | 2 | 2020 | 202 | 0.070 |
Why?
|
| Streptokinase | 4 | 2007 | 23 | 0.070 |
Why?
|
| Endoscopy | 1 | 2009 | 464 | 0.070 |
Why?
|
| Life Style | 3 | 2017 | 338 | 0.070 |
Why?
|
| Transplants | 1 | 2005 | 28 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2021 | 1330 | 0.070 |
Why?
|
| Models, Statistical | 3 | 2017 | 448 | 0.060 |
Why?
|
| Factor IX | 1 | 2005 | 3 | 0.060 |
Why?
|
| Perioperative Period | 2 | 2017 | 24 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2016 | 107 | 0.060 |
Why?
|
| Blood Coagulation Tests | 1 | 2004 | 31 | 0.060 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2004 | 19 | 0.060 |
Why?
|
| Calcium Chloride | 1 | 2004 | 38 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2017 | 453 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2007 | 346 | 0.060 |
Why?
|
| Naproxen | 1 | 2004 | 3 | 0.060 |
Why?
|
| Platelet Function Tests | 2 | 2016 | 10 | 0.060 |
Why?
|
| Ibuprofen | 1 | 2004 | 30 | 0.060 |
Why?
|
| Regional Medical Programs | 1 | 2004 | 22 | 0.060 |
Why?
|
| Platelet Count | 2 | 2018 | 100 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 73 | 0.060 |
Why?
|
| Health Plan Implementation | 1 | 2004 | 37 | 0.060 |
Why?
|
| Pulsatile Flow | 1 | 2004 | 20 | 0.060 |
Why?
|
| Journalism, Medical | 1 | 2004 | 2 | 0.060 |
Why?
|
| Drug Design | 1 | 2005 | 107 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2004 | 260 | 0.060 |
Why?
|
| Hemodynamics | 1 | 2007 | 705 | 0.060 |
Why?
|
| Drug Utilization | 2 | 2019 | 119 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2004 | 77 | 0.060 |
Why?
|
| Osteoarthritis | 1 | 2004 | 73 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2005 | 291 | 0.060 |
Why?
|
| Injections, Subcutaneous | 2 | 2019 | 87 | 0.060 |
Why?
|
| Integrin beta3 | 1 | 2004 | 35 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 2800 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2004 | 155 | 0.060 |
Why?
|
| Drug Industry | 1 | 2004 | 54 | 0.060 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2003 | 7 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 1040 | 0.060 |
Why?
|
| Patient Transfer | 1 | 2004 | 86 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 93 | 0.060 |
Why?
|
| Citric Acid | 1 | 2002 | 16 | 0.050 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2002 | 24 | 0.050 |
Why?
|
| Calcium | 1 | 2007 | 929 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2003 | 130 | 0.050 |
Why?
|
| Prothrombin Time | 1 | 2002 | 24 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2022 | 21 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 240 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2022 | 137 | 0.050 |
Why?
|
| Poverty | 1 | 2003 | 219 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 2 | 2015 | 198 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 3 | 2013 | 329 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2077 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2008 | 306 | 0.050 |
Why?
|
| Australia | 2 | 2014 | 235 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 236 | 0.050 |
Why?
|
| Anniversaries and Special Events | 1 | 2021 | 12 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 77 | 0.050 |
Why?
|
| Reference Standards | 1 | 2021 | 115 | 0.050 |
Why?
|
| Angiography | 2 | 2016 | 194 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 41 | 0.050 |
Why?
|
| Environmental Health | 1 | 2021 | 23 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 58 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 2 | 2013 | 72 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2020 | 55 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2022 | 330 | 0.050 |
Why?
|
| Torsades de Pointes | 1 | 2020 | 5 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2022 | 254 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 514 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 152 | 0.040 |
Why?
|
| Reference Values | 2 | 2013 | 579 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 41 | 0.040 |
Why?
|
| Equipment Design | 3 | 2007 | 500 | 0.040 |
Why?
|
| Professional Role | 1 | 2020 | 80 | 0.040 |
Why?
|
| New York | 1 | 2019 | 223 | 0.040 |
Why?
|
| Health Services | 1 | 2020 | 87 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 193 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2673 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 86 | 0.040 |
Why?
|
| Prosthesis Design | 2 | 2012 | 301 | 0.040 |
Why?
|
| Drug Delivery Systems | 3 | 2006 | 236 | 0.040 |
Why?
|
| Veterans Health | 1 | 2019 | 62 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 43 | 0.040 |
Why?
|
| Immobilization | 1 | 2018 | 26 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 109 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2018 | 31 | 0.040 |
Why?
|
| District of Columbia | 1 | 2018 | 23 | 0.040 |
Why?
|
| Sample Size | 1 | 2018 | 79 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2018 | 104 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 248 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2019 | 85 | 0.040 |
Why?
|
| Neoplasms | 1 | 2009 | 1667 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2021 | 335 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 307 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2008 | 304 | 0.040 |
Why?
|
| Probability | 2 | 2008 | 245 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2017 | 62 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 120 | 0.040 |
Why?
|
| Graft Survival | 2 | 2011 | 465 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2550 | 0.040 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2017 | 8 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 40 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 2324 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2021 | 718 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 39 | 0.030 |
Why?
|
| Hyperlipidemias | 2 | 2008 | 90 | 0.030 |
Why?
|
| Thailand | 1 | 2016 | 28 | 0.030 |
Why?
|
| Rats | 1 | 2004 | 5300 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 89 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 786 | 0.030 |
Why?
|
| Cell Phone | 1 | 2016 | 44 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 21 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 60 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 424 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 682 | 0.030 |
Why?
|
| Hyperplasia | 2 | 2005 | 89 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2016 | 379 | 0.030 |
Why?
|
| Necrosis | 2 | 2008 | 239 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 627 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 371 | 0.030 |
Why?
|
| Chest Pain | 2 | 2007 | 151 | 0.030 |
Why?
|
| Korea | 1 | 2014 | 13 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2018 | 326 | 0.030 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2015 | 61 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2014 | 5 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 10 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 11 | 0.030 |
Why?
|
| Contraindications | 2 | 2004 | 52 | 0.030 |
Why?
|
| Buffers | 1 | 2014 | 31 | 0.030 |
Why?
|
| Protective Factors | 1 | 2014 | 24 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 263 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 50 | 0.030 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 28 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2014 | 53 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 2 | 2006 | 177 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2004 | 58 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 2014 | 136 | 0.030 |
Why?
|
| Heart-Assist Devices | 1 | 2017 | 221 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2014 | 49 | 0.030 |
Why?
|
| Pyrroles | 1 | 2014 | 83 | 0.030 |
Why?
|
| Patient Preference | 1 | 2014 | 57 | 0.030 |
Why?
|
| Income | 2 | 2006 | 167 | 0.030 |
Why?
|
| Medical Informatics | 1 | 2014 | 71 | 0.030 |
Why?
|
| Pierre Robin Syndrome | 1 | 2013 | 7 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 689 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2014 | 178 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2004 | 219 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 124 | 0.030 |
Why?
|
| Injections | 1 | 2013 | 119 | 0.030 |
Why?
|
| Propensity Score | 1 | 2013 | 117 | 0.030 |
Why?
|
| Africa | 1 | 2012 | 41 | 0.030 |
Why?
|
| Mice | 1 | 2004 | 8474 | 0.030 |
Why?
|
| Protein Binding | 2 | 2006 | 1027 | 0.030 |
Why?
|
| Asia | 1 | 2012 | 59 | 0.030 |
Why?
|
| Medical Staff Privileges | 1 | 2012 | 2 | 0.030 |
Why?
|
| Knowledge Bases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2013 | 174 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 100 | 0.030 |
Why?
|
| Femur | 1 | 2013 | 113 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2012 | 74 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2013 | 100 | 0.030 |
Why?
|
| Monitoring, Physiologic | 2 | 2004 | 219 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 35 | 0.020 |
Why?
|
| Renal Artery Obstruction | 1 | 2011 | 29 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 123 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 168 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 79 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 25 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 2012 | 222 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2011 | 75 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2279 | 0.020 |
Why?
|
| Prothrombin | 1 | 2010 | 12 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2011 | 152 | 0.020 |
Why?
|
| Regeneration | 1 | 2011 | 105 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 120 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2010 | 80 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 164 | 0.020 |
Why?
|
| Sucrose | 1 | 2010 | 58 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 139 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 51 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2012 | 311 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 2011 | 203 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2011 | 208 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2009 | 6 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 57 | 0.020 |
Why?
|
| Echocardiography | 1 | 2012 | 515 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 42 | 0.020 |
Why?
|
| Blood Preservation | 1 | 2009 | 13 | 0.020 |
Why?
|
| Blood Cells | 1 | 2009 | 27 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 507 | 0.020 |
Why?
|
| Ezetimibe, Simvastatin Drug Combination | 1 | 2008 | 1 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 447 | 0.020 |
Why?
|
| Thoracic Arteries | 1 | 2008 | 10 | 0.020 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2008 | 9 | 0.020 |
Why?
|
| Hematocrit | 1 | 2008 | 70 | 0.020 |
Why?
|
| Observation | 1 | 2008 | 30 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1054 | 0.020 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2007 | 20 | 0.020 |
Why?
|
| Nitrates | 1 | 2007 | 61 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 148 | 0.020 |
Why?
|
| Femoral Vein | 1 | 2007 | 15 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 138 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 95 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2006 | 7 | 0.020 |
Why?
|
| Life Tables | 1 | 2006 | 29 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 246 | 0.020 |
Why?
|
| Arteries | 1 | 2006 | 108 | 0.020 |
Why?
|
| Device Removal | 1 | 2007 | 100 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2005 | 59 | 0.020 |
Why?
|
| E2F Transcription Factors | 1 | 2005 | 48 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2005 | 49 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2008 | 442 | 0.020 |
Why?
|
| Diclofenac | 1 | 2004 | 11 | 0.020 |
Why?
|
| Plasminogen Activators | 1 | 2004 | 19 | 0.010 |
Why?
|
| Counseling | 1 | 2006 | 280 | 0.010 |
Why?
|
| Emergency Treatment | 1 | 2004 | 52 | 0.010 |
Why?
|
| Ireland | 1 | 2004 | 13 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 2004 | 64 | 0.010 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2004 | 47 | 0.010 |
Why?
|
| Health Status | 1 | 2006 | 429 | 0.010 |
Why?
|
| Causality | 1 | 2003 | 82 | 0.010 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2003 | 8 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 172 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 133 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 442 | 0.010 |
Why?
|
| Health Services Research | 1 | 2003 | 209 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2002 | 50 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2002 | 130 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 706 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2006 | 1034 | 0.010 |
Why?
|